Clinical Trial Update: Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Update on a Phase 1/2 trial evaluating pembrolizumab with stereotactic body radiation therapy or wide-field radiation therapy in patients with non-small cell lu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING